8-K: Ernexa Therapeutics Faces Nasdaq Delisting Threat

Ernexa Therapeutics Inc. received a Nasdaq delisting notice for failing to maintain a minimum bid price, complicated by a prior reverse stock split.

Summary

• Ernexa Therapeutics Inc. received a written notice from the Nasdaq Listing Qualifications Department on March 18, 2026.
• The company's common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
• The company is not eligible for the standard 180-calendar day compliance period under Nasdaq Listing Rule 5810(c)(3)(A) due to having effected a reverse stock split over the prior one-year period.
• Ernexa Therapeutics Inc. intends to timely request a hearing before the Nasdaq Hearing Panel.
• The hearing request will automatically stay any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Panel.
• The Nasdaq Hearing Panel has the authority to grant an extension not to exceed 180 days from the date of the Notice.
• The company plans to present its strategy to regain compliance with the Minimum Bid Price Requirement to the Panel.
• There are no assurances that a favorable decision from the Panel will be obtained or that the company's securities will remain listed on The Nasdaq Capital Market.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly negative development, indicating significant operational and market challenges that threaten the company's ability to remain listed on a major exchange, severely impacting investor confidence.

Positives

• Company intends to request a hearing before the Nasdaq Hearing Panel, which will automatically stay any suspension or delisting action pending the hearing.

Negatives

• Received a delisting notice from Nasdaq for failing to maintain a minimum bid price of $1.00 per share.
• Violated Nasdaq Listing Rule 5550(a)(2) by failing to meet the minimum bid price requirement for 30 consecutive business days.
• Ineligible for the standard 180-day compliance period due to a reverse stock split effected within the prior one-year period.
• Uncertainty regarding the outcome of the Nasdaq Hearing Panel's decision.
• Risk that the company's securities may not remain listed on The Nasdaq Capital Market.

Risks

• No assurances of obtaining a favorable decision from the Nasdaq Hearing Panel.
• The company's securities may not remain listed on The Nasdaq Capital Market.
• Actual results may differ materially from forward-looking statements due to inherent risks and uncertainties.

Future Outlook

The company plans to request a hearing before the Nasdaq Hearing Panel and present a plan to regain compliance with the Minimum Bid Price Requirement. However, there are no assurances of a favorable decision or continued listing on The Nasdaq Capital Market.

Management Comments

• The Company intends to timely request a hearing before the Nasdaq Hearing Panel.

Industry Context

StockSavvy.ai notes that delisting notices for minimum bid price violations are a recurring challenge for smaller biotechnology companies, particularly those with early-stage pipelines or facing market skepticism. The ineligibility for the standard compliance period due to a recent reverse stock split highlights a more severe and persistent challenge, suggesting previous attempts to meet listing requirements have not been sustained. This situation often leads to increased volatility and reduced investor confidence, typical for companies struggling to maintain market capitalization and liquidity on major exchanges.

Comparison to Industry Standards

• StockSavvy.ai observes that while many companies face minimum bid price challenges, Ernexa Therapeutics' inability to utilize the standard 180-day compliance period due to a prior reverse stock split places it in a more precarious position compared to peers.
• This immediate need for a hearing and the lack of a grace period are less favorable than the typical Nasdaq delisting process, which usually offers a longer window for remediation.

Legal Proceedings

• Requesting a hearing before the Nasdaq Hearing Panel to appeal the delisting notice and present a compliance plan.

Stakeholder Impact

• Shareholders face potential loss of liquidity and market visibility if the company is delisted, along with increased volatility and uncertainty regarding their investment value.
• Employees may experience impacts on morale and future stability due to the company's precarious listing status.

Next Steps

• Timely request a hearing before the Nasdaq Hearing Panel.
• Present plans to regain compliance with the Minimum Bid Price Requirement to the Panel.

Key Dates

Recommendation

The immediate threat of delisting from Nasdaq, compounded by the ineligibility for the standard compliance period due to a recent reverse stock split, signals severe underlying issues with the company's market valuation and operational stability. The uncertainty of a favorable outcome from the Nasdaq Hearing Panel makes the stock highly speculative and carries significant downside risk for investors, warranting a strong sell recommendation.

Keywords

Nasdaq, delisting, minimum bid price, reverse stock split, 8-K, compliance, Ernexa Therapeutics, ERNA, ERNAW, biotech